ARINA-1 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
228	Bronchiolitis obliterans	1
299	Cystic fibrosis	1

228. Bronchiolitis obliterans

---

Clinical trials : 97 /  Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05654922 (ClinicalTrials.gov)	February 6, 2023	8/12/2022	Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant	A Phase 3, Open-label, Randomized, Standard of Care-controlled, Parallel Study Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants With a Bilateral Lung Transplant	Pre-Bronchiolitis Obliterans Syndrome	Drug: ARINA-1;Other: Standard of care only	Renovion, Inc.	NULL	Recruiting	18 Years	75 Years	All	100	Phase 3	United States

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05495243 (ClinicalTrials.gov)	October 3, 2022	24/6/2022	Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough	A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ARINA-1 in Adult Participants With Non-CF Bronchiectasis (NCFBE) With Excess Mucus and Cough	Non-cystic Fibrosis Bronchiectasis	Drug: ARINA-1;Drug: Placebo	Renovion, Inc.	NULL	Recruiting	18 Years	80 Years	All	50	Phase 2	United States